Don't 'Cell' Gamida, Buy It https://www.thestreet.com/investing/small-cap-stocks-that-could-see-big-gains-in-2021?puc=yahoo&cm_ven=YAHOO
Gamida Cell (GMDA) - Get Report is a biotechnology company that is using cell therapy to address blood cancers and serious blood disorders. Preliminary data has been robust and the company has already indicated that it met three secondary endpoints.
The company expected to report a full peer-reviewed data set in the first half of 2021. It originally intended to apply for a biological license application (BLA) on a rolling basis, but the FDA is requesting details about its planned commercial manufacturing sites. GMDA2021
Dan Rosenblum, the biotechnology expert at SharkInvesting.com, tells me, “What is really exciting about GMDA is the update on Natural Killer Cell Therapy GDA-201. In an oral presentation at the recent American Society of Hematology (ASH) 62nd Annual Meeting, it was shown that GDA-201 was well tolerated and no dose-limiting toxicities were observed in Phase 1 clinical study. GDA-201 demonstrated significant clinical activity in patients with non-Hodgkin lymphoma, with 13 complete responses and one partial response observed in 19 patients, for a response rate of 74%. ... Basically, the Natural killer cell technology produced cures in three out of four lymphoma patients.”
The company is a long way from final approval in late 2021, but the innovation of cell therapy is already attracting attention and there should be updates on progress in the first half of 2021 to drive the stock. GMDA is currently the largest holding in the ARK Israel Innovative Technology ETF at 247,218 shares.
I will be actively trading these stocks as they develop, but I feel that they have longer-term potential in the year ahead that will help to provide good support.